LYMPHOID NEOPLASIA Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation
نویسندگان
چکیده
1Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health (NIH), Bethesda, MD; 2Metabolism Branch and 3Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; 4Gene Expression Core Facility, Vascular Medicine Branch, National Heart, Lung and Blood Institute, NIH, Bethesda, MD; 5Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD; and 6Department of Laboratory Medicine, Clinical Center, NIH, Bethesda, MD
منابع مشابه
Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Bortezomib induces remissions in 30%-50% of patients with relapsed mantle cell lymphoma (MCL). Conversely, more than half of patients' tumors are intrinsically resistant to bortezomib. The molecular mechanism of resistance has not been defined. We generated a model of bortezomib-adapted subclones of the MCL cell lines JEKO and HBL2 that were 40- to 80-fold less sensitive to bortezomib than the ...
متن کاملLYMPHOID NEOPLASIA Mantle cell lymphoma activation enhances bortezomib sensitivity
Patients with mantle cell lymphoma (MCL) typically respond to initial treatment but subsequently relapse. This pattern suggests that a population of MCL cells is both drug resistant and capable of clonogenic growth. The intracellular enzyme retinaldehyde dehydrogenase (ALDH) provides resistance to several toxic agents. ALDH can also identify stem cells in normal adult tissues and tumorigenic ca...
متن کاملMarginal zone lymphomas with plasmacytic differentiation and related disorders.
Marginal zone lymphomas of all types (nodal, splenic, and extranodal mucosa-associated lymphoid tissue [MALT]) may show plasmacytic differentiation. Distinguishing marginal zone lymphomas from other small B-cell lymphomas with plasmacytic differentiation, especially lymphoplasmacytic lymphoma, or from plasma cell neoplasms may be challenging. Marginal zone lymphomas with plasmacytic differentia...
متن کاملThe BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Overexpression of antiapoptotic members of the Bcl-2 family is observed in approximately 80% of B-cell lymphomas, contributing to intrinsic and acquired drug resistance. Nullifying the antiapoptotic influence of these proteins can potentially overcome this resistance, and may complement conventional chemotherapy. ABT-737 is a BH3-only mimetic and potent inhibitor of the antiapoptotic Bcl-2 fami...
متن کاملLenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration-approved for bortezomib-resistant, relapsed/refractory mantle-cell lymphoma, lenalidomide has demonstrated efficacy in seve...
متن کامل